Adefovir Dipivoxil Alone or in Combination with Lamivudine for Three Months in Patients with Lamivudine Resistant Compensated Chronic Hepatitis B
Makaleler > Tam Makale · 2007
Yazarlar: Murat AKYILDIZ, Fulya GÜNŞAR, Galip ERSÖZ, Abdullah Zeki KARASU, Tankut ILTER, Yucel BATUR, Ulus Salih AKARCA
Digestive Diseases and Sciences, SCI Expanded İndekslerine Giren Dergi, Uluslararası, Wos, 2007, cilt 52, ss 3444-3447
DOI: 10.1007/s10620-006-9718-8
Özet
We studied clinical and laboratory effects of 3 months of lamivudine with adefovir combination and adefovir dipivoxil (AD) alone in the treatment of patients with lamivudine-resistant hepatitis B virus (HBV) infection. Eligible patients were hepatitis B surface antigen-positive men and women with compensated liver disease who were given lamivudine at least more than 6 months and had HBV polymerase gene mutation. Patients were assigned to receive adefovir 10 mg/day (Group 1) or adefovir 10 mg once daily and lamivudine 100 mg once daily combination during first 3 months, and then stopped lamivudine and continued adefovir (Group 2).